CY1115745T1 - Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου - Google Patents

Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου

Info

Publication number
CY1115745T1
CY1115745T1 CY20141100853T CY141100853T CY1115745T1 CY 1115745 T1 CY1115745 T1 CY 1115745T1 CY 20141100853 T CY20141100853 T CY 20141100853T CY 141100853 T CY141100853 T CY 141100853T CY 1115745 T1 CY1115745 T1 CY 1115745T1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
prevention
treatment
diseases
Prior art date
Application number
CY20141100853T
Other languages
English (en)
Inventor
Harmeet Sidhu
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35510266&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115745(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of CY1115745T1 publication Critical patent/CY1115745T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση περιλαμβάνει μεθόδους και συνθέσεις για τη μείωση οξαλικών σε ανθρώπους, ζώα και φυτά. Για παράδειγμα, η εφεύρεση παρέχει μεθόδους και συνθέσεις για την παροχή ενός ή περισσότερων ενζύμων τα οποία μειώνουν τα οξαλικά στις εντερικές οδούς ατόμων και ζώων. Οι μέθοδοι και οι συνθέσεις μπορεί να χρησιμοποιηθούν σε αντιμετώπιση και πρόληψη σχετιζόμενων με οξαλικά παθήσεων.
CY20141100853T 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου CY1115745T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/868,242 US8486389B2 (en) 1997-05-23 2004-06-15 Compositions and methods for treating or preventing oxalate-related disease
EP05786347.4A EP1771201B1 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease

Publications (1)

Publication Number Publication Date
CY1115745T1 true CY1115745T1 (el) 2017-01-25

Family

ID=35510266

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100853T CY1115745T1 (el) 2004-06-15 2014-10-16 Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY181101090T CY1120782T1 (el) 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101090T CY1120782T1 (el) 2004-06-15 2018-10-23 Συνθεσεις για την αντιμετωπιση ή την προληψη νοσου που σχετιζεται με οξαλικα

Country Status (13)

Country Link
US (3) US8486389B2 (el)
EP (2) EP2803366B1 (el)
CN (2) CN101166421A (el)
CY (2) CY1115745T1 (el)
DK (2) DK2803366T3 (el)
ES (2) ES2522898T3 (el)
HK (2) HK1198922A1 (el)
LT (1) LT2803366T (el)
PL (2) PL2803366T3 (el)
PT (2) PT2803366T (el)
SI (2) SI2803366T1 (el)
TR (1) TR201815200T4 (el)
WO (1) WO2005123116A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
CN1578833B (zh) * 2001-10-05 2010-05-26 奥克斯赛拉公司 降低流体中草酸(盐)浓度的材料和方法
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
EP1755655A4 (en) * 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
EP2465579A1 (en) 2005-06-10 2012-06-20 Althea Technologies, Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
AU2005339139A1 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
CN101405022A (zh) * 2005-12-16 2009-04-08 奥克斯赛拉公司 用于减少草酸盐的组合物和方法
PT2046373E (pt) * 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
EP2449098B1 (en) * 2009-07-02 2016-12-07 OxThera Intellectual Property AB Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
EP2270138B1 (en) 2009-07-02 2018-03-28 OxThera Intellectual Property AB Purification and isolation of recombinant oxalate degrading enzymes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2504428A4 (en) * 2009-11-25 2013-09-25 Captozyme Llc METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
ES2875060T3 (es) 2013-06-07 2021-11-08 Allena Pharmaceuticals Inc Composiciones y dispositivos para diálisis
JOP20200118A1 (ar) * 2013-07-05 2017-06-16 Oxthera Intellectual Property Ab مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس
KR20180044225A (ko) 2015-04-02 2018-05-02 캡토자임, 엘엘씨 불용성 및 가용성의 옥살레이트의 분해를 위한 고효율의 옥살레이트 분해 효소
US10765709B2 (en) 2016-06-13 2020-09-08 Oxthera Intellectual Property Compositions and methods for the treatment or prevention of oxalate-related disorders
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) * 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4888182A (en) 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5279827A (en) 1991-01-16 1994-01-18 Allegheny-Singer Research Institute Extract and pharmaceutical composition for treatment of calcium oxalate stone disease and viral infections
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
JPH08503851A (ja) 1992-11-30 1996-04-30 ゼネカ・リミテッド シュウ酸脱炭酸酵素
JPH08509018A (ja) 1993-04-16 1996-09-24 マコーミック アンド カンパニー，インク． カプセル化組成物
US5554147A (en) 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
WO1995031537A1 (en) 1994-05-18 1995-11-23 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US6214980B1 (en) 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
US20040120941A1 (en) 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
KR20010012845A (ko) 1997-05-23 2001-02-26 아익션 바이오테크놀로지, 인코퍼레이티드 옥살산염 관련 질병의 예방을 위한 옥살산염-분해 미생물또는 옥살산염-분해 효소
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US6080404A (en) 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
ES2326502T3 (es) 1998-10-09 2009-10-13 General Mills, Inc. Encapsulacion de componentes liquidos sensibles en una matriz para obtener particulas discretas de larga conservacion.
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
CN1365275A (zh) 1999-06-07 2002-08-21 南诺斯菲尔股份有限公司 包被颗粒的方法以及所得颗粒
DE10026541A1 (de) 2000-05-27 2001-11-29 Zeiss Carl Vorrichtung zur präzisen Positionierung eines Bauteils, insbesondere eines optischen Bauteiles
CN1578833B (zh) 2001-10-05 2010-05-26 奥克斯赛拉公司 降低流体中草酸(盐)浓度的材料和方法
US7407668B2 (en) 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
AU2003274918A1 (en) 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
EP1755655A4 (en) 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
AU2005339139A1 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
CN101405022A (zh) 2005-12-16 2009-04-08 奥克斯赛拉公司 用于减少草酸盐的组合物和方法
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
US20140030324A1 (en) 2014-01-30
EP2803366A2 (en) 2014-11-19
US10149866B2 (en) 2018-12-11
WO2005123116A2 (en) 2005-12-29
CY1120782T1 (el) 2019-12-11
ES2522898T3 (es) 2014-11-19
EP2803366A3 (en) 2015-02-18
SI2803366T1 (sl) 2018-12-31
TR201815200T4 (tr) 2018-11-21
EP1771201B1 (en) 2014-08-13
PL2803366T3 (pl) 2018-12-31
HK1198922A1 (en) 2015-06-19
SI1771201T1 (sl) 2014-12-31
EP1771201A4 (en) 2011-01-19
LT2803366T (lt) 2018-12-27
US10653726B2 (en) 2020-05-19
ES2692148T3 (es) 2018-11-30
EP1771201A2 (en) 2007-04-11
US20040234514A1 (en) 2004-11-25
WO2005123116A3 (en) 2008-01-03
US20190091268A1 (en) 2019-03-28
EP2803366B1 (en) 2018-08-01
PT1771201E (pt) 2014-11-06
PL1771201T3 (pl) 2015-01-30
CN101166421A (zh) 2008-04-23
PT2803366T (pt) 2018-11-06
DK1771201T3 (da) 2014-11-03
US8486389B2 (en) 2013-07-16
CN104998253A (zh) 2015-10-28
HK1216080A1 (zh) 2016-10-14
DK2803366T3 (en) 2018-11-05

Similar Documents

Publication Publication Date Title
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1116093T1 (el) Χρηση νιντεντανιμπης για την αγωγη της πνευμονικης ινωσεως
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
EA200701918A1 (ru) Белок липокалин
NO20084749L (no) Organiske forbindelser og deres anvendelser
CY1110954T1 (el) Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
NO20034056D0 (no) Proliferative sykdommer
HUP0302384A2 (hu) Sejtek bioenergia metabolizmusában szerepet játszó biokémiai vegyületeket tartalmazó készítmények és alkalmazásuk
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
ATE448232T1 (de) Substituierte heterozyklen
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
CY1116840T1 (el) Χρηση 24-norudca